AFP and hepatocellular carcinoma: Current AASLD guidelines recommend a one-size-fits-all screening strategy for HCC (abdominal ultrasound with or without serum AFP every six months) in patients with cirrhosis[38], regardless of etiology or the presence or absence of various risk factors.